Krishna Institute of Medical Sciences Limited
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers neurology, neurosurgery, psychiatry, and neuro rehabilitation; cardiology, cardiac and vascular surgery, heart transplant, and cardio rehabilitation; and pulmonology, interventional pulmonology, thoracic surgery, and lung transplant. It also provides medical and surgical gastroenterology, hepatobiliary pancreatic surgery, liver transplant, and bariatric surgery; ear, nose, throat, and head and neck surgery; and nephrology, urology, andrology, renal transplant, gynecology, urogynecology, IVF and art, fetal medicine, and obstetrics. In addition, the company offers orthopedics, arthroscopic and spine surgery, and ortho rehabilitation; medical surgical and radiation, and BMT and hematology; ophthalmology; dermatology, cosmetology, and plastic and reconstructive surgery; and clinical infectious diseases. Further, it provides imaging and interventional radiology; paediatrics and pediatric sub specialities, and neonatology; maxillo-facial surgery; OT and day care anaesthesia and pain medicine; and pathology, microbiology, and biochemistry. Additionally, the company offers molecular biology and clinical hematology; internal medicine, general surgery, and diabetology and endocrinology; and ICU, CTICU, SICU, NICU, PICU, neuro and ECMO ICU, and post transplant ICU services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Operating margin of 30.0% exceeds Healthcare median (24.8%)
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.38 K Cr | β | βΉ303.00 Cr | β | β | 14.0% | 13.3% | 28.9% |
| Mar 2024 | βΉ1.22 K Cr | β | βΉ235.00 Cr | β | β | 12.6% | 8.0% | -6.7% |
| Mar 2023 | βΉ1.13 K Cr | β | βΉ252.00 Cr | β | β | 15.5% | -1.0% | -9.4% |
| Mar 2022 | βΉ1.14 K Cr | β | βΉ278.00 Cr | β | β | 20.2% | 22.5% | 47.1% |
| Mar 2021 | βΉ933.00 Cr | β | βΉ189.00 Cr | β | β | 20.8% | 18.1% | 56.2% |
| Mar 2020 | βΉ790.00 Cr | β | βΉ121.00 Cr | β | β | 19.4% | 11.7% | -375.0% |
| Mar 2019 | βΉ707.00 Cr | β | βΉ-44.00 | β | β | -8.7% | 12.6% | -45.7% |
| Mar 2018 | βΉ628.00 Cr | β | βΉ-81.00 | β | β | 40.7% | 17.2% | -345.5% |
| Mar 2017 | βΉ536.00 Cr | β | βΉ33.00 Cr | β | β | 10.2% | 10.5% | 37.5% |
| Mar 2016 | βΉ485.00 Cr | β | βΉ24.00 Cr | β | β | 9.2% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,497 |
| Total Expenses | 1,076 |
| EBIT / Operating Profit | 421 |
| OPM % | 28% |
| Other Income | 80 |
| Finance Costs | 45 |
| Depreciation & Amortisation | 68 |
| Profit Before Tax | 388 |
| Tax % | - |
| Net Profit / PAT | 292 |
| EPS (βΉ) | 7.31 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Krishna Institute of Medical Sciences Limitedthis co. | βΉ24.92 K Cr | βΉ1.38 K Cr | 87.70 | 10.89 | 65.55 | 13.3% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |